The global Human Immune Globulin Intravenous market size was valued at USD 13750 million in 2023 and is forecast to a readjusted size of USD 21780 million by 2030 with a CAGR of 6.8% during review period.
Immune globulin听(Ig) short-term protection against hepatitis A and measles
The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.Furthermore, the rising awareness about bleeding disorders and the availability of comprehensive treatment programs have contributed to increased diagnosis rates and access to coagulation factor therapies. Improved reimbursement policies and healthcare infrastructure have also played a role in expanding market reach.
This report includes an overview of the development of the Human Immune Globulin Intravenous industry chain, the market status of Immunodeficiency (IVIg Liquid, IVIg Powder), Autoimmune Disease (IVIg Liquid, IVIg Powder), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Human Immune Globulin Intravenous.
Regionally, the report analyzes the Human Immune Globulin Intravenous markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Human Immune Globulin Intravenous market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Human Immune Globulin Intravenous market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Human Immune Globulin Intravenous industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., IVIg Liquid, IVIg Powder).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Human Immune Globulin Intravenous market.
Regional Analysis: The report involves examining the Human Immune Globulin Intravenous market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Human Immune Globulin Intravenous market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Human Immune Globulin Intravenous:
Company Analysis: Report covers individual Human Immune Globulin Intravenous manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Human Immune Globulin Intravenous This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Immunodeficiency, Autoimmune Disease).
Technology Analysis: Report covers specific technologies relevant to Human Immune Globulin Intravenous. It assesses the current state, advancements, and potential future developments in Human Immune Globulin Intravenous areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Human Immune Globulin Intravenous market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Human Immune Globulin Intravenous market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
麻豆原创 segment by Type
IVIg Liquid
IVIg Powder
麻豆原创 segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
Major players covered
Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Human Immune Globulin Intravenous product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Human Immune Globulin Intravenous, with price, sales, revenue and global market share of Human Immune Globulin Intravenous from 2019 to 2024.
Chapter 3, the Human Immune Globulin Intravenous competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Human Immune Globulin Intravenous breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Human Immune Globulin Intravenous market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Human Immune Globulin Intravenous.
Chapter 14 and 15, to describe Human Immune Globulin Intravenous sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Human Immune Globulin Intravenous
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Human Immune Globulin Intravenous Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 IVIg Liquid
1.3.3 IVIg Powder
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Human Immune Globulin Intravenous Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Immunodeficiency
1.4.3 Autoimmune Disease
1.4.4 Acute Infection
1.5 Global Human Immune Globulin Intravenous 麻豆原创 Size & Forecast
1.5.1 Global Human Immune Globulin Intravenous Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Human Immune Globulin Intravenous Sales Quantity (2019-2030)
1.5.3 Global Human Immune Globulin Intravenous Average Price (2019-2030)
2 Manufacturers Profiles
2.1 Takeda
2.1.1 Takeda Details
2.1.2 Takeda Major Business
2.1.3 Takeda Human Immune Globulin Intravenous Product and Services
2.1.4 Takeda Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Takeda Recent Developments/Updates
2.2 Grifols
2.2.1 Grifols Details
2.2.2 Grifols Major Business
2.2.3 Grifols Human Immune Globulin Intravenous Product and Services
2.2.4 Grifols Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Grifols Recent Developments/Updates
2.3 CSL
2.3.1 CSL Details
2.3.2 CSL Major Business
2.3.3 CSL Human Immune Globulin Intravenous Product and Services
2.3.4 CSL Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 CSL Recent Developments/Updates
2.4 Octapharma
2.4.1 Octapharma Details
2.4.2 Octapharma Major Business
2.4.3 Octapharma Human Immune Globulin Intravenous Product and Services
2.4.4 Octapharma Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Octapharma Recent Developments/Updates
2.5 Biotest
2.5.1 Biotest Details
2.5.2 Biotest Major Business
2.5.3 Biotest Human Immune Globulin Intravenous Product and Services
2.5.4 Biotest Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Biotest Recent Developments/Updates
2.6 Kedrion
2.6.1 Kedrion Details
2.6.2 Kedrion Major Business
2.6.3 Kedrion Human Immune Globulin Intravenous Product and Services
2.6.4 Kedrion Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Kedrion Recent Developments/Updates
2.7 Hualan Bio
2.7.1 Hualan Bio Details
2.7.2 Hualan Bio Major Business
2.7.3 Hualan Bio Human Immune Globulin Intravenous Product and Services
2.7.4 Hualan Bio Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Hualan Bio Recent Developments/Updates
2.8 CNBG
2.8.1 CNBG Details
2.8.2 CNBG Major Business
2.8.3 CNBG Human Immune Globulin Intravenous Product and Services
2.8.4 CNBG Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 CNBG Recent Developments/Updates
2.9 Shanghai RAAS
2.9.1 Shanghai RAAS Details
2.9.2 Shanghai RAAS Major Business
2.9.3 Shanghai RAAS Human Immune Globulin Intravenous Product and Services
2.9.4 Shanghai RAAS Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Shanghai RAAS Recent Developments/Updates
2.10 CBPO
2.10.1 CBPO Details
2.10.2 CBPO Major Business
2.10.3 CBPO Human Immune Globulin Intravenous Product and Services
2.10.4 CBPO Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 CBPO Recent Developments/Updates
2.11 LFB Group
2.11.1 LFB Group Details
2.11.2 LFB Group Major Business
2.11.3 LFB Group Human Immune Globulin Intravenous Product and Services
2.11.4 LFB Group Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 LFB Group Recent Developments/Updates
2.12 BPL
2.12.1 BPL Details
2.12.2 BPL Major Business
2.12.3 BPL Human Immune Globulin Intravenous Product and Services
2.12.4 BPL Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 BPL Recent Developments/Updates
2.13 Sichuan Yuanda Shuyang
2.13.1 Sichuan Yuanda Shuyang Details
2.13.2 Sichuan Yuanda Shuyang Major Business
2.13.3 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Product and Services
2.13.4 Sichuan Yuanda Shuyang Human Immune Globulin Intravenous Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Sichuan Yuanda Shuyang Recent Developments/Updates
3 Competitive Environment: Human Immune Globulin Intravenous by Manufacturer
3.1 Global Human Immune Globulin Intravenous Sales Quantity by Manufacturer (2019-2024)
3.2 Global Human Immune Globulin Intravenous Revenue by Manufacturer (2019-2024)
3.3 Global Human Immune Globulin Intravenous Average Price by Manufacturer (2019-2024)
3.4 麻豆原创 Share Analysis (2023)
3.4.1 Producer Shipments of Human Immune Globulin Intravenous by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2023
3.4.2 Top 3 Human Immune Globulin Intravenous Manufacturer 麻豆原创 Share in 2023
3.4.2 Top 6 Human Immune Globulin Intravenous Manufacturer 麻豆原创 Share in 2023
3.5 Human Immune Globulin Intravenous 麻豆原创: Overall Company Footprint Analysis
3.5.1 Human Immune Globulin Intravenous 麻豆原创: Region Footprint
3.5.2 Human Immune Globulin Intravenous 麻豆原创: Company Product Type Footprint
3.5.3 Human Immune Globulin Intravenous 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Human Immune Globulin Intravenous 麻豆原创 Size by Region
4.1.1 Global Human Immune Globulin Intravenous Sales Quantity by Region (2019-2030)
4.1.2 Global Human Immune Globulin Intravenous Consumption Value by Region (2019-2030)
4.1.3 Global Human Immune Globulin Intravenous Average Price by Region (2019-2030)
4.2 North America Human Immune Globulin Intravenous Consumption Value (2019-2030)
4.3 Europe Human Immune Globulin Intravenous Consumption Value (2019-2030)
4.4 Asia-Pacific Human Immune Globulin Intravenous Consumption Value (2019-2030)
4.5 South America Human Immune Globulin Intravenous Consumption Value (2019-2030)
4.6 Middle East and Africa Human Immune Globulin Intravenous Consumption Value (2019-2030)
5 麻豆原创 Segment by Type
5.1 Global Human Immune Globulin Intravenous Sales Quantity by Type (2019-2030)
5.2 Global Human Immune Globulin Intravenous Consumption Value by Type (2019-2030)
5.3 Global Human Immune Globulin Intravenous Average Price by Type (2019-2030)
6 麻豆原创 Segment by Application
6.1 Global Human Immune Globulin Intravenous Sales Quantity by Application (2019-2030)
6.2 Global Human Immune Globulin Intravenous Consumption Value by Application (2019-2030)
6.3 Global Human Immune Globulin Intravenous Average Price by Application (2019-2030)
7 North America
7.1 North America Human Immune Globulin Intravenous Sales Quantity by Type (2019-2030)
7.2 North America Human Immune Globulin Intravenous Sales Quantity by Application (2019-2030)
7.3 North America Human Immune Globulin Intravenous 麻豆原创 Size by Country
7.3.1 North America Human Immune Globulin Intravenous Sales Quantity by Country (2019-2030)
7.3.2 North America Human Immune Globulin Intravenous Consumption Value by Country (2019-2030)
7.3.3 United States 麻豆原创 Size and Forecast (2019-2030)
7.3.4 Canada 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Mexico 麻豆原创 Size and Forecast (2019-2030)
8 Europe
8.1 Europe Human Immune Globulin Intravenous Sales Quantity by Type (2019-2030)
8.2 Europe Human Immune Globulin Intravenous Sales Quantity by Application (2019-2030)
8.3 Europe Human Immune Globulin Intravenous 麻豆原创 Size by Country
8.3.1 Europe Human Immune Globulin Intravenous Sales Quantity by Country (2019-2030)
8.3.2 Europe Human Immune Globulin Intravenous Consumption Value by Country (2019-2030)
8.3.3 Germany 麻豆原创 Size and Forecast (2019-2030)
8.3.4 France 麻豆原创 Size and Forecast (2019-2030)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Russia 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Italy 麻豆原创 Size and Forecast (2019-2030)
9 Asia-Pacific
9.1 Asia-Pacific Human Immune Globulin Intravenous Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Human Immune Globulin Intravenous Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Human Immune Globulin Intravenous 麻豆原创 Size by Region
9.3.1 Asia-Pacific Human Immune Globulin Intravenous Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Human Immune Globulin Intravenous Consumption Value by Region (2019-2030)
9.3.3 China 麻豆原创 Size and Forecast (2019-2030)
9.3.4 Japan 麻豆原创 Size and Forecast (2019-2030)
9.3.5 Korea 麻豆原创 Size and Forecast (2019-2030)
9.3.6 India 麻豆原创 Size and Forecast (2019-2030)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2019-2030)
9.3.8 Australia 麻豆原创 Size and Forecast (2019-2030)
10 South America
10.1 South America Human Immune Globulin Intravenous Sales Quantity by Type (2019-2030)
10.2 South America Human Immune Globulin Intravenous Sales Quantity by Application (2019-2030)
10.3 South America Human Immune Globulin Intravenous 麻豆原创 Size by Country
10.3.1 South America Human Immune Globulin Intravenous Sales Quantity by Country (2019-2030)
10.3.2 South America Human Immune Globulin Intravenous Consumption Value by Country (2019-2030)
10.3.3 Brazil 麻豆原创 Size and Forecast (2019-2030)
10.3.4 Argentina 麻豆原创 Size and Forecast (2019-2030)
11 Middle East & Africa
11.1 Middle East & Africa Human Immune Globulin Intravenous Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Human Immune Globulin Intravenous Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Human Immune Globulin Intravenous 麻豆原创 Size by Country
11.3.1 Middle East & Africa Human Immune Globulin Intravenous Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Human Immune Globulin Intravenous Consumption Value by Country (2019-2030)
11.3.3 Turkey 麻豆原创 Size and Forecast (2019-2030)
11.3.4 Egypt 麻豆原创 Size and Forecast (2019-2030)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2019-2030)
11.3.6 South Africa 麻豆原创 Size and Forecast (2019-2030)
12 麻豆原创 Dynamics
12.1 Human Immune Globulin Intravenous 麻豆原创 Drivers
12.2 Human Immune Globulin Intravenous 麻豆原创 Restraints
12.3 Human Immune Globulin Intravenous Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Human Immune Globulin Intravenous and Key Manufacturers
13.2 Manufacturing Costs Percentage of Human Immune Globulin Intravenous
13.3 Human Immune Globulin Intravenous Production Process
13.4 Human Immune Globulin Intravenous Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Human Immune Globulin Intravenous Typical Distributors
14.3 Human Immune Globulin Intravenous Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Takeda
Grifols
CSL
Octapharma
Biotest
Kedrion
Hualan Bio
CNBG
Shanghai RAAS
CBPO
LFB Group
BPL
Sichuan Yuanda Shuyang
听
听
*If Applicable.
